Emerging Trends and Growth Drivers in the Myeloproliferative Disorders Drugs Market Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Myeloproliferative Disorders Drugs Market From 2025 to 2029?
In recent times, the market for drugs treating myeloproliferative disorders has consistently expanded. It’s projected to increase from $9.47 billion in 2024 to $9.83 billion in 2025, translating to a compound annual growth rate (CAGR) of 3.8%. Factors such as a rise in the occurrence of myeloproliferative disorders, advancements in the knowledge of disease mechanisms, progression in clinical research and drug synthesis, enhancements in diagnosis methods and screening procedures, and patient advocacy and public awareness have spurred growth during the historic period.
In the coming years, the market for drugs treating myeloproliferative disorders is anticipated to experience consistant growth. It is expected to balloon to “$11.51 billion by 2029 with a 4.0% compound annual growth rate (CAGR). This upward trend in the forecast period can be linked to factors such as an aging population, advancements in precision medicine, the development of new treatment methods, a global interest in rare diseases, government actions, and health care policies. Precision medical approaches, investigational therapy clinical trials, improved symptom management, the growing use of ruxolitinib, and a focus on disease biomarkers are some key trends to be observed in the forecast period.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10681&type=smp
What Elements Are Contributing To Growth In The Myeloproliferative Disorders Drugs Market?
An increase in the number of cases of myeloproliferative disorders is projected to fuel the expansion of the market for drugs targeting these conditions. One or more hematologic cell lines in peripheral blood experience uncontrolled cellular growth in myeloproliferative disorders, setting them apart from acute leukemia. The predominant causes of myeloproliferative disorders are genetic abnormalities, excessive exposure to radiation, electrical wiring, or chemicals, along with the aging population. Drugs for treating myeloproliferative diseases work by blocking the BCR-ABL protein. They achieve this by latching onto the ATP pocket in the active site, which inhibits the downstream phosphorylation of the target protein and aids in the management of the myeloproliferative disorder. For example, the National Institute of Health, a medical research organization based in the US, reported in August 2022 that chronic myelogenous leukemia diagnoses in 2022 were more common in males, with roughly 2.4 new cases per 100,000, as opposed to 1.4 new cases per 100,000 in females. This a notable increase compared to 1.7 new cases per 100,000 population for both genders annually in 2020. Consequently, the upsurge in myeloproliferative disorder cases is influencing the growth of the market for drugs treating these diseases.
The myeloproliferative disorders drugs market covered in this report is segmented –
1) By Type: Primary Myelofibrosis, Polycythemia Vera (PV), Essential Thrombocythemia (ET), Chronic Eosinophilic Leukemia Or Hyper eosinophilic Syndrome (HES), Systemic Masto cytosis (SM)
2) By Drug Type: JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Other Drug Types
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Stores, Drug Stores
Subsegments:
1) By Primary Myelofibrosis: JAK Inhibitors, Immunomodulatory Agents, Supportive Care
2) By Polycythemia Vera (PV): JAK Inhibitors, Hydroxyurea, Phlebotomy, Interferon-alpha
3) By Essential Thrombocythemia (ET): JAK Inhibitors, Hydroxyurea, Anagrelide, Interferon-alpha
4) By Chronic Eosinophilic Leukemia or Hyper Eosinophilic Syndrome (HES): Tyrosine Kinase Inhibitors, Corticosteroids, Interferon-alpha
5) By Systemic Mastocytosis (SM): Tyrosine Kinase Inhibitors, Corticosteroids, Antihistamines, Immunotherapy
How Are Key Trends Driving Expansion In The Myeloproliferative Disorders Drugs Industry?
The market for myeloproliferative disorder drugs is witnessing a key trend in product innovation, with leading companies focusing on developing innovative products to consolidate their market presence. Take for example GSK PLC, a pharmaceutical and biotechnology firm hailing from the UK. They announced the FDA’s approval for the drug momelotinib, used for treating primary myelofibrosis, an MPD type, in September 2023. This potentially groundbreaking medication operates uniquely by blocking three pivotal pathways – activin A receptor type I (ACVR1), Janus kinase (JAK) 1, and JAK2. This inhibition of JAK1 and JAK2 might relieve splenomegaly and constitutional symptoms. Moreover, it reduces the elevated circulating hepcidin in myelofibrosis, a contributor to anemia, through the direct inhibition of ACVR1.
Who Are The Key Contributors To Growth In The Myeloproliferative Disorders Drugs Market?
Major companies operating in the myeloproliferative disorders drugs market include Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Incyte Corporation, Eli Lilly and Co, F Hoffmann-La Roche Ltd., Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals plc, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International Gmbh, Sanofi Aventis Inc., AstraZeneca AB, Apotex Inc, Celgene Co., Gamida Cell Ltd., Geron Co., Promedior Inc., Johnson & Johnson Private Limited, AbbVie Inc., AOP Orphan Pharmaceuticals AG, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Chemical Pharma Co. Ltd., Eisai Pharmaceuticals India Pvt. Ltd.
Which Region Is Projected To Lead The Myeloproliferative Disorders Drugs Market By 2025?
North America was the largest region in the myeloproliferative disorder drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global myeloproliferative disorder drugs market report during the forecast period. The regions covered in the myeloproliferative disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10681&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
